Triclabendazole is reported to be highly effective in treatment of human fascioliasis. We present 7 of 19 selected cases of human fascioliasis referred to our center in the Cusco region of Peru that failed to respond to triclabendazole. These were mostly symptomatic adults of both sexes that continued passing Fasciola eggs in the stool despite multiple treatments with 2 doses of triclabendazole at 10 mg/kg per dose. We documented the presence of eggs by rapid sedimentation and Kato Katz tests after each treatment course. We found that repeated triclabendazole courses were not effective against fascioliasis in this group of people. These findings suggest that resistance to triclabendazole may be an emerging problem in the Andes.
References
[1]
Elliott TP, Kelley JM, Rawlin G, Spithill TW. High prevalence of fasciolosis and evaluation of drug efficacy against Fasciola hepatica in dairy cattle in the Maffra and Bairnsdale districts of Gippsland, Victoria, Australia. Vet Parasitol. 2015 Apr 15;209(1–2):117–24. doi: 10.1016/j.vetpar.2015.02.014. pmid:25771931
[2]
Kaplan RM. Fasciola hepatica: a review of the economic impact in cattle and considerations for control. Vet Ther Res Appl Vet Med. 2001;2(1):40–50.
[3]
Mezo M, González-Warleta M, Castro-Hermida JA, Mui？o L, Ubeira FM. Association between anti-F. hepatica antibody levels in milk and production losses in dairy cows. Vet Parasitol. 2011 Aug 25;180(3–4):237–42. doi: 10.1016/j.vetpar.2011.03.009. pmid:21459514
[4]
Kuerpick B, Schnieder T, Strube C. Seasonal pattern of Fasciola hepatica antibodies in dairy herds in Northern Germany. Parasitol Res. 2012 May 8;111(3):1085–92. doi: 10.1007/s00436-012-2935-5. pmid:22565401
[5]
Charlier J, Duchateau L, Claerebout E, Williams D, Vercruysse J. Associations between anti-Fasciola hepatica antibody levels in bulk-tank milk samples and production parameters in dairy herds. Prev Vet Med. 2007 Jan;78(1):57–66. pmid:17095109 doi: 10.1016/j.prevetmed.2006.09.010
[6]
Sargison ND, Wilson DJ, Penny CD, Bartley DJ. Unexpected production loss caused by helminth parasites in weaned beef calves. Vet Rec. 2010 Nov 6;167(19):752–4. doi: 10.1136/vr.c5428. pmid:21257513
[7]
Fürst T, Keiser J, Utzinger J. Global burden of human food-borne trematodiasis: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Mar;12(3):210–21. doi: 10.1016/S1473-3099(11)70294-8. pmid:22108757
[8]
Lopez M, White AC, Cabada MM. Burden of Fasciola hepatica infection among children from Paucartambo in Cusco, Peru. Am J Trop Med Hyg. 2012 Mar 1;86(3):481–5. doi: 10.4269/ajtmh.2012.11-0448. pmid:22403322
[9]
Cabada MM, Goodrich MR, Graham B, Villanueva-Meyer PG, Lopez M, Arque E, et al. Fascioliasis and eosinophilia in the highlands of Cuzco, Peru and their association with water and socioeconomic factors. Am J Trop Med Hyg. 2014 Nov;91(5):989–93. doi: 10.4269/ajtmh.14-0169. pmid:25200257
[10]
El-Shazly AM, El-Nahas HA, Abdel-Mageed AA, Beshbishi SN El, Azab MS, Abou El Hasan M, et al. Human fascioliasis and anaemia in Dakahlia Governorate, Egypt. J Egypt Soc Parasitol. 2005 Aug;35(2):421–32. pmid:16083056
[11]
Keiser J, Engels D, Büscher G, Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs. 2005 Dec;14(12):1513–26. pmid:16307491 doi: 10.1517/13543784.14.12.1513
[12]
Sargison ND, Scott PR. Diagnosis and economic consequences of triclabendazole resistance in Fasciola hepatica in a sheep flock in south-east Scotland. Vet Rec. 2011 Feb 12;168(6):159. doi: 10.1136/vr.c5332. pmid:21493511
[13]
Sargison N. Diagnosis of triclabendazole resistance in Fasciola hepatica. Vet Rec. 2012 Aug 11;171(6):151–2. doi: 10.1136/vr.e5357. pmid:22890399
[14]
Gordon D, Zadoks R, Skuce P, Sargison N. Confirmation of triclabendazole resistance in liver fluke in the UK. Vet Rec. 2012 Aug 11;171(6):159–60. doi: 10.1136/vr.e5381. pmid:22890401
[15]
Ortiz P, Scarcella S, Cerna C, Rosales C, Cabrera M, Guzmán M, et al. Resistance of Fasciola hepatica against Triclabendazole in cattle in Cajamarca (Peru): a clinical trial and an in vivo efficacy test in sheep. Vet Parasitol. 2013 Jul 1;195(1–2):118–21. doi: 10.1016/j.vetpar.2013.01.001. pmid:23352107
[16]
Winkelhagen AJS, Mank T, de Vries PJ, Soetekouw R. Apparent Triclabendazole-resistant human Fasciola hepatica infection, the Netherlands. Emerg Infect Dis. 2012 Jun;18(6):1028–9. doi: 10.3201/eid1806.120302. pmid:22607719
[17]
Gil LC, Díaz A, Rueda C, Martínez C, Castillo D, Apt W. Resistant human fasciolasis: Report of four patients. Rev Médica Chile. 2014 Oct;142(10):1330–3. doi: 10.4067/s0034-98872014001000014
[18]
Raunelli F, Gonzalez S. Strategic control and prevalence of Fasciola hepatica in Cajamarca, Peru. A pilot study. Intern J Appl Res Vet Med 2009:7;145–52. Accessed 24 November 2015. Available at:
[19]
Identification of intestinal parasites. Bench Aids for the Diagnosis of Intestinal Parasites, World Health Organization 2012. Accessed 24 November 2015. Available at:
[20]
Pica-Mattoccia L, Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol 2004;34(4):527–33 pmid:15013742 doi: 10.1016/j.ijpara.2003.12.003
[21]
Grandière-Pérez L, Ansart S, Paris L, Faussart A, Jaureguiberry S, Grivois J- P, et al. Efficacy of praziquantel during the incubation and invasive phase of Schistosoma haematobium schistosomiasis in 18 travelers. Am J Trop Med Hyg. 2006 May 1;74(5):814–8. pmid:16687686
[22]
Duthaler U, Smith TA, Keiser J. In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78. Antimicrob Agents Chemother 2010;54(11):4596–604 doi: 10.1128/AAC.00828-10. pmid:20733042
[23]
Chen JX, Chen MX, Ai L, Xu XN, Jiao JM, Zhu TJ, Su HY, Zang W, Luo JJ, Guo YH, Lv S, Zhou XN. An Outbreak of Human Fascioliasis gigantica in Southwest China. PLoS One. 2013 Aug 8;8(8):e71520. doi: 10.1371/journal.pone.0071520. pmid:23951181
[24]
Gu W, Su HY, Zou J, Li QC, Chen BY, Lin CS, Jiao JM. Clinical diagnosis and treatment in an outbreak of Fasciola gigantica infection in Yunnan Province. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2012;30(6):455–9 [Abstract] pmid:23484257
[25]
Marcos LA, Tagle M, Terashima A, Bussalleu A, Ramirez C, Carrasco C, Valdez L, Huerta-Mercado J, Freedman DO, Vinetz JM, Gotuzzo E. Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis. Am J Trop Med Hyg 2008;78(2):222–7 pmid:18256419
[26]
Fairweather I. Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy? Vet Parasitol. 2011 Aug 4;180(1–2):133–43. doi: 10.1016/j.vetpar.2011.05.034. pmid:21703766
[27]
Savage J, Meaney M, Brennan GP, Hoey E, Trudgett A, Fairweather I. Effect of the P-glycoprotein inhibitor, R(+)-verapamil on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica. Vet Parasitol. 2013 Jul 1;195(1–2):72–86. doi: 10.1016/j.vetpar.2013.03.007. pmid:23597772
[28]
Robinson MW, Lawson J, Trudgett A, Hoey EM, Fairweather I. The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol Res. 2004 Feb;92(3):205–10. pmid:14652740 doi: 10.1007/s00436-003-1003-6
[29]
Favennec L, Jave Ortiz J, Gargala G, Lopez Chegne N, Ayoub A, Rossignol JF. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther. 2003 Jan;17(2):265–70. pmid:12534412 doi: 10.1046/j.1365-2036.2003.01419.x
[30]
Zumaquero-Ríos JL, Sarracent-Pérez J, Rojas-García R, Rojas-Rivero L, Martínez-Tovilla Y, Valero MA, et al. Fascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: epidemiology and treatment with nitazoxanide. PLoS Negl Trop Dis. 2013 Nov;7(11):e2553. doi: 10.1371/journal.pntd.0002553. pmid:24278492
